PriceTracker GLP-1

What FDA’s record states

FDA record for the warning letter to Mane & Steel, LLC. dba Mane & Steel
FieldWhat FDA’s record statesSource
RecipientMane & Steel, LLC. dba Mane & SteelFDA letter
LocationSacramento, CAFDA letter
Letter dateSep 9, 2025FDA letter
Posted by FDASep 16, 2025FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)FDA letter
MARCS-CMS number716455FDA letter
GLP-1 drugs namedSemaglutideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].”FDA warning letter to Mane & Steel, LLC. dba Mane & Steel, Sep 9, 2025 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

And 48 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters